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Key Points
•Use of ATG was asso-
ciated with reduced in-
cidence of graft-versus
host disease in the
patients undergoing
allo-HCT with TBI.
•Use of ATG for GVHD
prophylaxis did not im-
pact disease relapse
or NRM.
The impact of the use of antithymocyte globulin (ATG) following a total body irradiation
(TBI)–based myeloablative conditioning regimen has been poorly explored. We
retrospectively analyzed 724 patients who underwent a first allogeneic hematopoietic cell
transplantation (allo-HCT) following a TBI-based conditioning regimen for acute myeloid
leukemia (AML) and compared the outcomes of 251 (35%) patients who received ATG
(ATG group) with 473 (65%) patients who did not (non-ATG group). Median follow-up of
surviving patients was 59 months (interquartile range, 28-83). The cumulative incidence of
grade II-IV acute graft-versus-host disease (aGVHD) for non-ATG and ATG groups in the first
100 days was 33% vs 24%, respectively (P 5 .0098). The 2-year cumulative incidence of
chronic graft-versus-host disease (cGVHD) was reduced significantly in the ATG group in
comparison with the non-ATG group (46% vs 34%, P 5 .003). Using multivariate analysis,
in vivo T-cell depletion (ATG group) was independently associated with a decreased
incidence of grade II-IV aGVHD (hazard ratio [HR], 0.28; P , .001), grade III-IV aGVHD
(HR, 0.21; P , .001), cGVHD (HR, 0.63; P 5 .02), and nonrelapse mortality (NRM) (HR, 0.54;
P5 .02). Relapse risk, overall survival, and leukemia-free survival were similar between the
2 groups. Our results suggest that the addition of ATG to TBI-based myeloablative
conditioning for allo-HCT in AML patients results in a significant reduction in aGVHD
and cGVHD, translating into a significant reduction in NRM without increasing the
relapse rate.
Introduction
Allogeneic hematopoietic cell transplantation (allo-HCT) cures a wide range of hematological disorders.
Allo-HCT with a myeloablative conditioning (MAC) regimen remains the treatment of choice for high-risk
acute myeloid leukemia (AML).1-3 However, the use of peripheral blood stem cell (PBSC) grafts from
HLA-matched related donors (MRDs) or HLA-matched unrelated donors (MUDs) with MAC increases
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the risk of chronic graft-versus-host disease (cGVHD).4-6 cGVHD is
the leading cause of morbidity and mortality in long-term survivors
after allo-HCT6-9 (40%-60%) and leads to decreased quality of
life.9,10 The incidence of cGVHD showed a gradual increase
from 1995 to 2007.11
The use of in vivo T-cell depletion (TCD) with anti–T-cell or
antithymocyte globulin (ATG) products has been reported to be
associated with decreased graft-versus-host disease (GVHD).12,13
A number of phase 2 studies have evaluated the effect of ATG in
patients receiving unmanipulated bone marrow (BM) grafts after
MAC.13 These studies showed that ATG decreased the risk of
acute graft-versus-host disease (aGVHD) and cGVHD, without
increasing nonrelapse mortality (NRM), and improved quality of
life. ATG has also been shown, in 2 randomized trials, to decrease
the incidence of cGVHD in long-term survivors without adversely
affecting the incidence of disease relapse, serious infection, or
overall survival (OS)14-18; however, ATG has not been adopted
routinely.
The above-mentioned prospective randomized studies have also
shown that in vivo TCD with ATG reduces the incidence of cGVHD
without increasing the risk of relapse in allo-HCT with PBSC grafts
from MRDs or MUDs after conventional cyclophosphamide-based
MAC regimens for AML.14,15,19 Heterogeneity between groups in
terms of conditioning or types of disease limits the interpretation
of these data. Also, the number of patients receiving total body
irradiation (TBI)–based ablative regimens in these studies was small,
regardless of graft source or donor type. This raises questions
about the impact of the use of ATG in TBI-based MAC regimens,
in which the balance between GVHD and graft-versus-leukemia
(GVL) effects of allo-HCT might be more sensitive to in vivo
TCD. Very limited data exist on the potential effect of ATG in this
context.
With the objective to explore the impact of the use of ATG on the
TBI-based MAC regimen, we chose to retrospectively analyze
a cohort of 724 adult patients receiving allo-HCT for AML follow-
ing a TBI-based MAC regimen. In this homogeneous cohort of
patients, we compared transplant outcomes of 251 patients who
had received ATG for GVHD prophylaxis with the 473 patients
who had not. The analysis tests the hypothesis that ATG before
allo-HCT decreases the risk of GVHD without compromising GVL
effects.
Methods
Study design and data collection
This is a retrospective multicenter analysis using the data set of the
Acute Leukemia Working Party of the European Society for Blood
and Marrow Transplantation (EBMT) group registry. The EBMT
is a voluntary working group of .600 transplant centers that
are required to report all consecutive stem cell transplantations
and follow-ups once a year. Audits are routinely performed to
determine the accuracy of the data. The study was planned and
approved by the Acute Leukemia Working Party of the EBMT.
Informed consent was obtained from all patients to use their personal
information for research purposes. The study was conducted in
accordance with the Declaration of Helsinki and Good Clinical
Practice guidelines. Eligibility criteria for this analysis included
patients older than 18 years of age with AML who underwent a first
allo-HCT from a matched sibling (n 5 412) or 9/10 or 10/10 MUD
(n 5 312), following a TBI ($8-Gy)-based MAC regimen, between
2008 and 2016. Exclusion criteria were previous allogeneic or cord
blood transplantation, ex vivo T-cell–depleted hematopoietic cell
graft, and lack of information on cytogenetics. Data collected
included recipient and donor characteristics (age, sex, cytomeg-
alovirus [CMV] serostatus), disease characteristics and status
at transplant; year of transplant and interval from diagnosis to
transplant, and transplant-related factors, including conditioning
regimen, use and dose of ATG for pretransplant in vivo TCD,
stem cell source (BM or peripheral blood [PB]), and posttransplant
GVHD prophylaxis. GVHD prophylaxis regimens were dependent
on the centers’ protocols. We did not have information about the
brand of ATG formulation (thymoglobin versus Grafalon). Grading
of aGVHD was performed using established criteria.20 cGVHD was
classified as limited or extensive, according to published criteria.21
For the purpose of this study, all necessary data were collected
according to the EBMT guidelines, using the EBMT minimum
essential data forms. The list of institutions reporting data included
in this study is provided in the supplemental data.
Statistical analysis
Study end points were engraftment, incidence, and severity of
aGVHD and cGVHD, primary disease relapse incidence (RI),
NRM, leukemia-free survival (LFS), OS, and GVHD and relapse-
free survival (GRFS). Start time was the date of transplant for
all end points. LFS was defined as survival without relapse or
progression, NRMwas defined as death without relapse/progression,
and GRFS was defined as survival with no evidence of relapse/
progression, grade III-IV aGVHD, or severe cGVHD, as defined by
Ruggeri et al for registry-based studies.22 Cumulative incidence
functions were used to estimate RI and NRM in a competing risk
setting, because death and relapse compete with each other. For
estimating the cumulative incidence of aGVHD and cGVHD, we
considered relapse and death to be competing events. Groups
were compared using the x2 test for qualitative variables, and the
Mann-Whitney U test was applied for continuous parameters. Uni-
variate comparisons were performed using the log-rank test for
OS, LFS, and GRFS and using Gray’s test for RI, NRM, and GVHD
cumulative incidences. Multivariate analyses were performed using
the Cox proportional hazards model for all end points. Factors
differing in terms of distribution between the groups, factors
associated with 1 of the outcomes in univariate analysis, and all
factors known to be potential risk factors were included in the
final model. To test for a center effect, we introduced a random
effect or frailty for each center into the model, as described
previously.23 All tests were 2-sided. The type I error rate was fixed at
0.05 for the determination of factors associated with time-to-event
outcomes. Statistical analyses were performed with SPSS 24.0
(IBM Corp., Armonk, NY) and R 3.4.0 software (R Development
Core Team, Vienna, Austria) packages.
Results
Patient, transplant, and disease characteristics
Patient, disease, and transplant characteristics are summarized in
Table 1.
A total of 724 patients with AML who had received an allo-HCT
from a matched sibling (n 5 412) or a 9/10 or 10/10 MUD (n 5
312), following a TBI ($8-Gy)-based MAC regimen, between 2008
and 2016 was included in the study. Among the total population
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Table 1. Baseline patient, disease, and transplant characteristics
ATG group (n 5 251) Non-ATG group (n 5 473) P
Follow-up, median (IQR), mo 58.1 (24.0-83.3) 58.9 (31.6-83.5)
Patient age at allo-HCT, median (range), y 39 (18.1-67.7) 39.6 (18.1-62.1) .34
Patient sex
Male 141 (56.18) 251 (53.07) .42
Female 110 (43.82) 222 (46.93)
Disease status at allo-HCT
CR1 164 (65.34) 325 (68.71) .65
CR21 55 (21.91) 93 (19.66)
Advanced 32 (12.75) 55 (11.63)
Cytogenetics risk category*
Good 45 (17.93) 90 (19.03) .66
Intermediate 134 (53.39) 262 (55.39)
Poor 72 (28.68) 121 (25.58)
FLT3-ITD
Negative 64 (58.18) 132 (59.46) .82
Positive 46 (41.82) 90 (40.54)
Missing 141 251
NPM1 mutation
Negative 57 (65.52) 102 (62.58) .65
Positive 30 (34.48) 61 (37.42)
Missing 164 310
KPS at allo-HCT
,90% 47 (19.75) 97 (21.85) .52
$90% 191 (80.25) 347 (78.15)
Missing 13 29
Graft source
BM 43 (17.13) 102 (21.56) .16
PB 208 (82.87) 371 (78.44)
Donor type
MSD 27 (10.76) 385 (81.4) ,.01
UD 10/10 164 (65.34) 72 (15.22)
UD 9/10 60 (23.90) 16 (3.38)
Locus mismatch in UD 9/10
A 16 (26.7) 5 (31.25)
B 8 (13.3) 4 (25.00)
C 19 (31.7) 4 (25.00)
DR 5 (8.30) 2 (12.50)
DQ 12 (20.0) 1 (6.25)
Female donor/male recipient
No 209 (83.6) 369 (78.01) .07
Yes 41 (16.4) 104 (21.99)
Missing 1 0
Patient CMV serology
Negative 87 (34.94) 191 (41.34) .10
Positive 162 (65.06) 271 (58.66)
Missing 2 11
Unless otherwise noted, data are n (%). Percentages do not include "missing" data.
CR1, first complete remission; CR21, second or later complete remission; CSA, cyclosporin; Cy, cyclophosphamide; DLI, donor lymphocyte infusion; Flu, fludarabine; HCT-CI, hematopoietic
cell transplantation–comorbidity index; IQR, interquartile range; IST, immunosuppressive therapy; KPS, Karnofsky performance status; MMF, mycophenolate mofetil; MSD, matched sibling donor;
MTX, methotrexate; TACRO, tacrolimus; UD, unrelated donor; 6, with or without.
*Based on European Leukemia Net risk stratification.24
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of patients, 473 (65%) did not receive ATG within the condition-
ing regimen (non-ATG group), whereas 251 (35%) received
ATG (ATG group). Other than ATG, GVHD prophylaxis was
mainly based on the association of cyclosporine and methotrex-
ate in both groups (74% and 72% in the non-ATG and ATG
groups, respectively). The choice of GVHD prophylaxis was
dependent on transplant center protocols and strategies for
transplantation.
There were no significant differences in patient and disease
characteristics between the ATG and non-ATG groups (Table 1).
There was no difference in terms of the cytogenetic risk category
based on European Leukemia Net stratification24 between the
2 groups. Cyclophosphamide and TBI (Cy-TBI) was used more
frequently in the non-ATG group (93% vs 84% in the ATG group,
P , .0001). Unrelated donor was used for 89% of the patients in
the ATG group vs 19% in the non-ATG group (P , .001). There
were more patients in the ATG group with 9/10 MRDs compared
with the non-ATG group (24% vs 3%). The majority of the patients
received PB as the stem cell source (78% in the non-ATG group vs
83% in the ATG group, P5 not statistically significant). The median
follow-up was 59 months (interquartile range [IQR], 28-83) and was
similar in the non-ATG group (59 months; IQR, 32-84) and the ATG
group (58 months; IQR, 24-83).
Impact of ATG on engraftment and GVHD
Engraftment and incidences of acute and chronic GVHD are
shown in Tables 1 and 2. There was no difference with regard to
engraftment rate between the non-ATG and ATG groups (99%
in both groups). The median time to neutrophil engraftment
(first day of 3 consecutive days with absolute neutrophil count
.0.5 3 109/L) was longer in the ATG group (19 days vs
17 days in non-ATG group, P , .001). The day-30 cumulative
incidence of neutrophil engraftment was 98% in the non-ATG
group and 96% in the ATG group. Two ATG recipients and 3
patients in the non-ATG group died before engraftment before
day 28.
Using univariate analysis, in vivo TCD (ATG group) was significantly
associated with a reduced risk for grade II-IV and grade III-IV
aGVHD (Table 2). Day-100 cumulative incidences of grade II-IV
and grade III-IV GVHD were 33% vs 24% (P 5 .01) and 13% vs
Table 1. (continued)
ATG group (n 5 251) Non-ATG group (n 5 473) P
Donor CMV serology
Negative 142 (56.57) 224 (48.7) .05
Positive 109 (43.43) 236 (51.3)
Missing 0 13
HCT-CI at allo-HCT
,3 72 (77.42) 150 (85.71) .09
$3 21 (22.58) 25 (14.29)
Missing 158 298
Conditioning regimen
Cy-TBI 212 (84.46) 442 (93.45) ,.001
Flu-TBI 39 (15.54) 31 (6.55)
Associated IST
CSA 7 (2.79) 12 (2.54) .12
CSA 1 MTX 182 (72.51) 351 (74.21)
CSA 1 MMF 6 MTX 35 (13.94) 42 (8.88)
TACRO 6 other 18 (7.17) 54 (11.41)
Other 9 (3.59) 14 (2.96)
Type of DLI
No DLI 227 (90.8) 443 (93.66) .31
Preemptive 7 (2.8) 7 (1.48)
After relapse 16 (6.4) 23 (4.86)
Missing 1 0
Graft failure
Graft failure 3 (1.2) 5 (1.06) 1.0
Missing 2 3
Unless otherwise noted, data are n (%). Percentages do not include "missing" data.
CR1, first complete remission; CR21, second or later complete remission; CSA, cyclosporin; Cy, cyclophosphamide; DLI, donor lymphocyte infusion; Flu, fludarabine; HCT-CI,
hematopoietic cell transplantation–comorbidity index; IQR, interquartile range; IST, immunosuppressive therapy; KPS, Karnofsky performance status; MMF, mycophenolate mofetil; MSD,
matched sibling donor; MTX, methotrexate; TACRO, tacrolimus; UD, unrelated donor; 6, with or without.
*Based on European Leukemia Net risk stratification.24
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7% (P 5 .0092), respectively, in the non-ATG and ATG groups.
Using multivariate analysis, in vivo TCD (ATG group) was indepen-
dently associated with a decreased risk for grade II-IV aGVHD
(hazard ratio [HR], 0.28; 95% confidence interval [CI], 0.18-0.44;
P , .0001) and grade III-IV aGVHD (HR, 0.21; 95% CI, 0.10-0.43;
P , .0001). The other factors significantly associated with aGVHD
are summarized in Tables 2 and 3.
Two-year cumulative incidences of overall and extensive cGVHD
were significantly reduced in the ATG group in comparison with
the non-ATG group (46% vs 34% for overall cGVHD, P 5 .003;
22% vs 16% for extensive cGVHD, P 5 .01) (Table 2; Figure 1).
As shown in Table 4, GVHD-related deaths accounted for 23%
(n 5 42) and 20% (n 5 20) of all causes of death in the non-ATG
and ATG groups, respectively (P 5 .66). On multivariate analysis,
the use of ATG was associated with a reduced risk for cGVHD
development (overall, HR, 0.63; 95% CI, 0.42-0.94; P 5 .02;
extensive, HR, 0.69; 95% CI, 0.38-1.23; P 5 .21) (Table 3;
Figure 1). The other factors associated with cGVHD are summarized
in Tables 2 and 3.
Toxicity and NRM
Two-year NRM for the entire cohort was 16% (95% CI, 13.6-19.1).
Using univariate analysis, the cumulative incidence of 2-year NRM
was similar between the groups (16%; 95% CI, 12.8-19.6 for
non-ATG group and 17%; 95% CI, 12.2-21.7 for ATG group)
(Table 2). Other than GVHD, the main causes of death from NRM
in the non-ATG and ATG groups were infections, in 21 (11%) and
14 (14%) patients, respectively, and veno-occlusive disease, in
4 (2%) and 1 (1%) patient, respectively (Table 4). One patient in
each group died from an unspecified lymphoproliferative disor-
der, and 1 patient in the ATG group died from posttransplant
lymphoproliferative disease. We have included a detailed descrip-
tion of other causes of death in supplemental Table 2. Using
multivariate analysis, in vivo TCD (ATG group) was indepen-
dently associated with a decreased risk for NRM (HR, 0.54;
95% CI, 0.32-0.91; P 5 .02). The other factors associated with
NRM are summarized in Tables 2 and 3.
Use of ATG had no impact on relapse incidence
Two-year cumulative incidence of relapse in the entire cohort of
patients was 24.5% (95% CI, 22.2-28.8) and represented the main
cause of death in both groups: 53% of all causes of death in the
non-ATG group and 47% of all causes of death in the ATG group
(Table 4). Using univariate analysis, the use of ATG had no impact
on the 2-year cumulative incidence of relapse, which was 25%
(95% CI, 21.1-29.3) of the patients in the non-ATG group and
26% (95% CI, 20.6-31.9) of those in the ATG group (P 5 .78)
(Table 2; Figure 1). The absence of the impact of ATG on relapse
risk was confirmed using multivariate analysis (HR 5 1.45, 95% CI,
0.90-2.34; P 5 .13). The other factors associated with RI are
summarized in Table 2 and Table 3.
Survival: OS, LFS, and GRFS
Two-year OS rate for the entire cohort was 63.2% (95% CI, 59.5-
66.9). On univariate analysis, OS was not different between the
groups (2-year: non-ATG 64%, 95% CI, 59.1-68.2; ATG: 62%,
95% CI, 56.1-68.6). (Table 2; Figure 1). Two-year LFS for the
entire cohort was 58% (95% CI, 54.5-62.1). Using univari-
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(non-ATG: 59%, 95% CI, 54.2-63.5; ATG: 57%, 95% CI, 50.9-
63.6) (Table 2; Figure 1). Two-year GRFS for the entire cohort
was 42% (95% CI, 37.9-45.5). Using univariate analysis, 2-year
GRFS was not different between the groups (non-ATG: 41%,
95% CI, 36.2-45.6; ATG: 43%, 95% CI, 36.8-49.8) (Table 2;
Figure 1).
Multivariate analysis adjusted for age, recipient and donor sex,
disease, disease risk, Karnofsky performance score, condition-
ing regimen, cytogenetic risk, CMV serostatus, and graft source
confirmed that there was no impact of ATG on OS, LFS, or
GRFS. The other factors associated with OS, LFS, and GRFS
are summarized in Tables 2 and 3.
NRME
Time from transplant (years)
0.0























473 280 216 185 158 121
251
no ATG
ATG 141 107 86 69 62
number of at-risk patients
GRFSC
Time from transplant (years)
0.0













464 203 150 127 108 78
245
no ATG
ATG 108 78 62 50 47
number of at-risk patients
0.0






























Time from transplant (days)
453 357 295 265 237
233
no ATG
ATG 192 175 150 127
number of at-risk patients
cGVHD
Time from transplant (years)
0.0
































83 48 39 35
number of at-risk patients
LFSD
Time from transplant (years)
0.0





















473 280 216 185 158 121
251
no ATG
ATG 141 107 86 69 62
number of at-risk patients
OSF
Time from transplant (years)
0.0


















473 319 239 203 170 129
251
no ATG
ATG 156 118 94 80 67
number of at-risk patients
Figure 1. Impact of ATG on transplant outcome after TBI-based myeloablative regimens. (A) Adjusted grade II-IV aGVHD. (B) cGVHD. (C) GVHD and GRFS. (D)
LFS. (E) NRM. (F) OS.
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Discussion
The impact of the use of ATG following a TBI-based MAC regimen
has been poorly explored. A recent prospective double-blind
phase 3 study of ATG vs placebo in patients with myelodys-
plastic syndrome or acute leukemia who underwent allo-HCT
from a MUD following MAC regimens reported inferior PFS
and OS in the ATG arm, especially in the TBI cohort. However,
the study was limited by the small number of patients receiv-
ing a TBI-based conditioning regimen (placebo, n 5 37 vs ATG
group, n 5 31).25 In the absence of large prospective studies
and to better understand the impact of ATG on a TBI-based
MAC regimen in AML, we analyzed the effect of ATG in a large
homogenous cohort of AML patients undergoing allo-HCT with
TBI, with and without ATG. Contrary to previous reports on small
series, our data showed that addition of ATG to a TBI-based
conditioning regimen, followed by allo-HCT for AML, resulted in
a significant reduction in aGVHD and cGVHD, translating into
a significant reduction in NRM without increasing the relapse
rate. These findings become more important when one consid-
ers that most patients in the ATG group were transplanted from
an unrelated donor compared with the non-ATG group. This find-
ing is of great importance, because cGVHD and the associated
immunosuppression are the primary causes of morbidity and
mortality in long-term survivors after allo-HCT and contribute
directly or indirectly to most late complications.
The use of TBI-based MAC regimens has been decreasing as
a result of equally effective chemotherapy-based regimens and
possibly because of concerns about an increased risk for late
effects with TBI-based regimens.26 However, TBI remains an
integral part of the conditioning in hematopoietic cell transplanta-
tion for high-risk malignancies, especially advanced leukemias. It
is possible that integration of ATG into a TBI-based regimen might
be beneficial to long-term follow-up by preventing late relapse,
as well as decreasing late complications after hematopoietic
cell transplantation, but this needs further study.
The traditional preparative myeloablative regimens for patients
with AML include Cy-TBI and the combination of busulfan 1
cyclophosphamide or busulfan1 fludarabine.27-29 Several retrospec-
tive registry-based and randomized studies compared Cy-TBI with
busulfan1 cyclophosphamide or busulfan1 fludarabine in patients
with AML and reported conflicting results regarding outcome and
toxic effects.2,27,30 However, no large study has directly compared
the long-term outcome between chemotherapy-based conditioning
regimens and TBI-based MAC regimens including ATG.
Our data indicate that TBI 1 ATG is an effective conditioning
regimen for allo-HCT in patients with AML, with a lower short-
term toxicity profile compared with a regimen without ATG. This
makes TBI 1 ATG potentially applicable to high-risk patients
with advanced disease. Further studies are needed to confirm
the superiority of TBI 1 ATG over TBI-based regimens without
ATG or chemotherapy-based myeloablative regimens.
The increased use of PBSC grafts (nearly 80% of stem cell grafts
now used in Europe)4,5,31 is also associated with a higher incidence
of aGVHD and cGVHD, even with HLA-identical sibling donors.4-6,11
It may be appropriate to consider the use of ATG, especially in
patients receiving TBI-based PBSC grafts, and it might improve
overall outcome by decreasing GVHD and related late complica-
tions. As reported in other settings of allo-HCT,12-15,17,32-36 this
study confirms that the addition of ATG significantly reduces, after
adjustment for other factors, the risk of developing aGVHD (HR,
0.28; P , .001) and cGVHD (HR, 0.627; P 5 .02). Such a
reduction in GVHD incidence was not associated with a reduced
effect of GVL, because the use of ATG did not impact RI.
A recently published25 prospective randomized double-blind
trial showed decreased OS and PFS when ATG was added to
tacrolimus and methotrexate as an immunosuppressive regimen,
in recipients of MAC MUD allo-HCT. However, several other open-
label randomized trials14,18,19 have reported a benefit of ATG
with a lower incidence of cGVHD without negatively impacting
PFS or OS. It is unclear why the study by Soiffer et al25 did not
recapitulate outcomes from prior studies. An important explanation
for the difference in outcomes may be related to the impact of the
conditioning regimen on absolute lymphocyte count (ALC) and
the interaction between ALC and ATG. Multiple studies, including
the 1 by Soiffer et al,25 found a striking relationship between low
ALC (more commonly seen with TBI-based regimens) at the time of
ATG administration and inferior PFS and OS. The low ALC before
allo-HCT likely resulted in less binding of ATG to lymphocytes,
with subsequently delayed clearance and higher concentrations
of ATG after allo-HCT.37-39
Routine use of lower-dosing (30 mg/kg total) schedules of ATG,
as in the study by Kröger et al,19 could potentially maintain protec-
tive effects against cGVHD but not increase mortality.12,13 In our
study, most patients had received an ATG dose, 6 mg/kg (median
dose in our study was 5 mg/kg), so we could not analyze the impact
of the ATG dose on outcomes in our series. The question remains
whether we can decrease the ATG dose with TBI-based MAC
regimens. Kennedy et al37 have shown that the PB ALC on the day
of ATG administration and the total dose of ATG (range, 428.8-
833.6 mg) interacted to predict transplant outcomes. For low-
recipient ALC (10th percentile, or 0.563 102/mL), a higher total
ATG dose was associated with a greater risk for death, whereas for
high-recipient ALC (90th percentile, or 24.96 3 102/mL), a higher
total ATG dose was associated with a lower risk for death. Patients
receiving TBI-based ablation are likely to develop early lymphopenia
due to the strong myeloablative and lymphoablative effects of TBI
compared with chemotherapy-based MAC regimens, and transplant
Table 4. Major causes of death among the ATG and non-ATG groups
Cause of death ATG group (n 5 101) Non-ATG group (n 5 192)
Cardiac toxicity 1 (1.0) 2 (1.1)
Hemorrhage 4 (4.0) 0 (0)
Graft failure 0 (0) 1 (0.5)
Veno-occlusive disease 1 (1.0) 4 (2.1)
Infection 14 (14.2) 21 (11.2)
Interstitial pneumonitis 1 (1.0) 5 (2.7)
GVHD 20 (20.2) 42 (22.5)
Relapsed AML 47 (47.5) 100 (53.5)
Second malignancy 0 (0) 3 (1.6)
Other NRM 11 (11.1) 9 (4.8)
Missing 2 5
Data are n (%). Percentages do not include "missing" data.
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outcome can be improved further by lowering the ATG dose in this
group of patients. The interaction between ATG and its target, the
recipient lymphocyte, could represent a new paradigm for ATG dosing,
and it may now be timely to explore the individualized ATG dosing in
patients receiving TBI-based MAC regimens based on real-time ALC
measurements to further improve transplant outcomes.37 Another
potential variable is the difference in ATG formulations (thymoglobin
versus Grafalon) used across the studies.40,41 It is unknown whether
in vivo TCD is comparable between these 2 formulations because
of the absence of dose equivalence and head-to-head comparisons
between thymoglobin and Grafalon. In a meta-analysis of prospective
studies, Gagelmann et al showed that Grafalon was associated with
improved GVHD (acute and chronic) rates compared with thymoglo-
bin.40We did not have information about the brand of ATG used in the
current analysis, which is a limitation of this study. A prospective study
will be required to define the optimal dose and formulation of ATG.
Why does the significant reduction in aGVHD and cGVHD not
translate into better OS in our series? The most likely explanations
could be the improved supportive treatment and the handling of
immunosuppressive measures over time that resulted in better
survival, despite an increased risk for aGVHD and cGVHD, in the
non-ATG group.4,6,7,32,42,43 Although cGVHD has been associ-
ated with GVL effects,4,5,44 it is also the leading cause of mortality/
morbidity in long-term survivors and impairs quality of life.7-9,45 Given
the long-term of effects of cGVHD, extended follow-up might yield
different results; specifically, quality-of-life measures, together with
other patient-reported outcomes, will be important end points to
analyze at a future date. As other strategies for TCD (posttransplant
cyclophosphamide) are being developed, the role of ATG in GVHD
prevention will need to be validated in a prospective fashion.
In summary, incorporation of ATG-based in vivo TCD in TBI-based
MAC for allo-HCT in AML resulted in lower GVHD rates and improved
NRM, without increasing the disease relapse rate. Although this is
a registry-based observational study, it is the largest analysis of its
kind and it demands a prospective validation of the role of ATG in TBI-
based MAC. Future studies exploring ALC-based dynamic dosing of
ATG may establish in vivo TCD as an important GVHD-prevention
strategy.
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32. Savani BN, Labopin M, Kröger N, et al. Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning
mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT.
Haematologica. 2016;101(6):773-780.
33. Russell JA, Turner AR, Larratt L, et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including
pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant.
2007;13(3):299-306.
34. Mohty M, Bay JO, Faucher C, et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte
globulin-based reduced-intensity preparative regimen. Blood. 2003;102(2):470-476.
35. Rubio MT, D’Aveni-Piney M, Labopin M, et al. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid
leukemia in first complete remission conditioned with a fludarabine IV-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working
Party. J Hematol Oncol. 2017;10(1):31.
36. Storek J, Mohty M, Boelens JJ. Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;
21(6):959-970.
37. Kennedy VE, Chen H, Savani BN, et al. Optimizing antithymocyte globulin dosing for unrelated donor allogeneic hematopoietic cell transplantation based
on recipient absolute lymphocyte count. Biol Blood Marrow Transplant. 2018;24(1):150-155.
9 JULY 2019 x VOLUME 3, NUMBER 13 ATG IN TBI-BASED ABLATIVE REGIMENS 1959
38. Admiraal R, van Kesteren C, Jol-van der Zijde CM, et al. Association between anti-thymocyte globulin exposure and CD41 immune reconstitution in
paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Lancet Haematol. 2015;2(5):e194-e203.
39. Admiraal R, Nierkens S, deWitte MA, et al. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic
cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis. Lancet Haematol. 2017;4(4):e183-e191.
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